Back to search results

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

Abroad (travel likely)RecruitingPHASE1

Conditions

Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • START - Midwest - EDOS, Grand Rapids, Michigan, United States

  • START - San Antonio - EDOS, San Antonio, Texas, United States

  • National Taiwan University Hospital, Taipei, Taipei City, Taiwan

  • National Cheng Kung University Hospital, Tainan, Taiwan

Study leads

  • Clinical Trials

    Study Director

    Genentech, Inc.

View source on ClinicalTrials.gov(opens in a new tab)